On December 29, 2017, ContraVir Pharmaceuticals, Inc. announced that John Sullivan-Bolyai will step down as Chief Medical Officer and take on a new role in the company, effective December 29, 2017. Dr. Sullivan-Bolyai will serve as a part-time consultant to the company, where he will remain involved in key strategic decisions, as well as medical and clinical affairs.